Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Respiration === The octopus uses gills as its respiratory surface. The gill is composed of branchial ganglia and a series of folded lamellae. Primary lamellae extend out to form demi branches and are further folded to form the secondary free folded lamellae, which are only attached at their tops and bottoms. The tertiary lamellae are formed by folding the secondary lamellae in a fan-like shape. Water moves slowly in one direction over the gills and lamellae, into the mantle cavity and out of the octopus' funnel. The structure of the octopus' gills allows for a high amount of oxygen uptake; up to 65% in water at 20 °C (68 °F). The thin skin of the octopus accounted for a large portion of oxygen uptake in an in-vitro study; the estimate suggests around 41% of all oxygen absorption is through the skin when at rest. This number is affected by the activity of the animal – the oxygen uptake increases when the octopus is exercising due to its entire body being constantly exposed to water, but the total amount of oxygen absorption through skin is actually decreased to 33% as a result of the metabolic cost of swimming. When the animal is curled up after eating, its absorption through its skin can drop to 3% of its total oxygen uptake. The octopus' respiratory pigment, hemocyanin, also assists in increasing oxygen uptake. Octopuses can maintain a constant oxygen uptake even when oxygen concentrations in the water decrease to around 3.5 kPa (0.51 psi) or 31.6% saturation (standard deviation 8.3%).
The limestone walls and towers of the Kremlin were built in 1366–1368. A distinct architectural school emerged in the late 14th century. The khan of the Golden Horde initially backed Moscow in an effort to halt the eastward expansion of the Grand Duchy of Lithuania, but he continued to meddle in Moscow's relations with other Russian princes to prevent it from becoming too strong. In 1353, the Black Death spread from northwestern Russia to Moscow, causing the deaths of ruler Simeon of Moscow, his sons, and the metropolitan. The ruling family of Moscow remained small as a result, and a new vertical pattern was defined: princely succession from father to son. During the reign of Dmitry Donskoy, the Moscow principality expanded significantly in size. In 1380, Dmitry led a united Russian army to victory over the Mongols in the Battle of Kulikovo, which increased Moscow's prestige and solidified the status of its rulers as military leaders of the nation. Following Dmitry's death in 1389, the thrones of Vladimir and Moscow were permanently united. During the reign of Vasily II, a civil war broke out after Yury of Zvenigorod challenged the succession of his nephew in 1425. Moscow switched hands numerous times; Yury's son, Dmitry Shemyaka, continued to resist until his appanage center of Galich was captured in 1450. In ecclesiastical matters, Vasily disapproved of the Council of Florence, leading him to arrest the metropolitan when he returned in 1441 for having signed it.
=== Adverse events === Acupuncture is generally safe when administered by an experienced, appropriately trained practitioner using clean-needle technique and sterile single-use needles. When improperly delivered it can cause adverse effects. Accidents and infections are associated with infractions of sterile technique or neglect on the part of the practitioner. To reduce the risk of serious adverse events after acupuncture, acupuncturists should be trained sufficiently. A 2009 overview of Cochrane reviews found acupuncture is not effective for a wide range of conditions. People with serious spinal disease, such as cancer or infection, are not good candidates for acupuncture. Contraindications to acupuncture (conditions that should not be treated with acupuncture) include coagulopathy disorders (e.g. hemophilia and advanced liver disease), warfarin use, severe psychiatric disorders (e.g. psychosis), and skin infections or skin trauma (e.g. burns). Further, electroacupuncture should be avoided at the spot of implanted electrical devices (such as pacemakers). A 2011 systematic review of systematic reviews (internationally and without language restrictions) found that serious complications following acupuncture continue to be reported. Between 2000 and 2009, ninety-five cases of serious adverse events, including five deaths, were reported. Many such events are not inherent to acupuncture but are due to malpractice of acupuncturists. This might be why such complications have not been reported in surveys of adequately trained acupuncturists.
== Overview == In laboratory use, droppers should not be used for work involving high accuracy since droppers are not designed to measure specific volume; however, it can be used to add drops of reagents. Each type of dropper is designed to produce a specific drop volume, but this is not highly precise. Before using a dropper, the tip should be carefully examined for cracks. To increase accuracy, the pipette is to be rinsed with the reagent. To use the dropper, the bulb is squeezed to expel air out of the pipette and the tip of the pipette is submerged into the solution vertically. The bulb is slowly released to draw the solution up, making sure that the solution does not overshoot into the bulb or else it may get contaminated. To dispense the reagent, the tip is held against the side of the target container at a 30 to 45 degrees angle. Broken pasteur pipettes should be disposed of in an appropriate glassware container.
Sources: en.wikipedia.org
In 1993, Hazleton, Besselaar, and SciCor were combined into Corning Pharmaceutical Services, then Corning Life Sciences. In 1995, Corning Pharmaceutical Services acquired National Packaging Systems, an Allentown, Pennsylvania-based clinical trial packaging company. In 1997, Corning completed the corporate spin-off of its laboratory testing business as Quest Diagnostics and its pharmaceutical services business as Covance. In the fourth quarter of 1998, the company acquired GDXI, which undertakes the capture and interpretation of electrocardiograms, and Berkeley Antibody Company, which provides contract services in custom antibody production, applied immunology, and custom animal testing to support the medical device industry and preclinical evaluations, for a total of $26 million in cash.
The native tribes of East Malaysia have their own languages which are related to, but easily distinguishable from, Malay. Iban is the main tribal language in Sarawak while Dusunic and Kadazan languages are spoken by the natives in Sabah. Chinese Malaysians predominantly speak Chinese dialects from the southern part of China. The more common Chinese varieties in the country are Mandarin, Cantonese, Hokkien, and so on. The Tamil language is used predominantly by the majority of Malaysian Indians. A small number of Malaysians have European ancestry and speak creole languages, such as the Portuguese-based Malaccan Creoles, and the Spanish-based Chavacano language.
Achondrogenesis, type 2 is an uncommon skeletal dysplasia that is autosomal dominant and occurs at a frequency of approximately 0.2 per 100,000 births. Also known by the name Langer–Saldino achondrogenesis, it is one of the fatal short-limbed dwarfisms linked to structural mutations in type II collagen. Typically, achondrogenesis type II manifests in the perinatal period as short stature, edema/hydropic look, narrow chest with pulmonary hypoplasia, severely short limbs (micromelia), and extraskeletal characteristics (e.g., flat midface, Pierre Robin sequence). Most of these babies are stillborn, delivered before their due date, or die from cardiorespiratory failure soon after delivery, meaning that they do not live to term.
Fialuridine (FIAU) is a synthetic, solid, fluorinated nucleoside analogue of thymidine that was investigated as a treatment for chronic hepatitis B virus infection (HBV) in the early 1990s. Its effectiveness was evaluated during a Phase II clinical trial over a six-month course, with 24 patients treated. FIAU was provided by Oclassen Pharmaceuticals and administered under an Investigational New Drug Application held by Eli Lilly and Company. Administration of FIAU resulted in antiviral activity, alongside several side effects which resulted in the termination of some clinical trials. Investigations found that affected patients suffered a depletion of mitochondrial DNA (mtDNA) in both liver and muscle tissue, establishing mitochondrial dysfunction as a contributing mechanism to toxicity. The FIAU trial is considered a landmark case in drug production and influenced subsequent drug safety assessments regarding mitochondrial toxicity.
At the present time the Department promotes various scientific fields, running the whole gamut of base branches of classical physical chemistry: thermodynamics, kinetics, electrochemistry, catalysis, sorption processes. As the subjects of research, organic compounds unite all the aforesaid research areas. Over the last years staff members of the Department of Physical Chemistry made reports at conferences in many countries of the world: Canada, Poland, Republic of South Africa, Italy, Germany, Portugal, Czech Republic, USA, Ireland, Croatia, Spain, Sweden, Japan, Brazil. The head of the Department is Professor Boris N. Solomonov, Doctor of Science in Chemistry. The Department conducts research in the following fields:
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.